Drug Trial Radar · NCT07367724
Ademetionine in Obstructive Hypertrophic Cardiomyopathy
Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Dec 31, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- China National Center for Cardiovascular DiseasesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Jan 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, double-blind, randomized controlled Phase 2 trial designed to evaluate the safety and efficacy of Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM). The study will recruit patients with oHCM who, under double-blind conditions, will be randomly assigned to either the Ademetionine group or the placebo group. Follow-up visits will be conducted every 4 weeks until 16 weeks from baseline. After 16 weeks, the study will evaluating the effect of Ademetionine on exercise capacity, heart failure symptoms, cardiac structure and function, and quality of life, as well as safety and tolerability of Ademetionine in this patient population.
Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Ademetionine 1,4-ButanedisulfonateDrug
Ademetionine 1,4-Butanedisulfonate is the currently available marketed oral pharmaceutical formulation of S-adenosylmethionine. Its brand name is Ximeixin in China.
PlaceboDrug
The placebo is a starch tablet identical in appearance, odor, and other physical properties.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in pVO₂ by CPET from baseline to Week 16Time frame: From enrollment to the end of treatment at 16 weeks
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Fuwai Hospital
Beijing, China · Recruiting
Zhongshan Hospital, Shanghai Medical College of Fudan University
Shanghai, China · Recruiting
The First Affiliated Hospital of Xinjiang Medical University
Xinjiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.